BAKU, Azerbaijan, February 26. Iran has announced the launch of the production of Dioxide Tellurium powder, which is the raw material for the treatment of thyroid (parathyroid) cancer with the use of Iodine-131 drug, Trend reports.
In this regard, an event was held today at the Tehran reactor with the participation of Iran's Vice President and the Head of the Atomic Energy Organization Mohammad Eslami.
The event featured the presentation of the said raw material for the drug.
During the event, it was mentioned that the final process in the production of stable isotopes is Tellurium 130 (TE 130). This product was irradiated directly at the Tehran reactor, and Iodine-131 pharmaceutical drug was produced.
Moreover, it was emphasized that since the full production process of this radio pharmaceutical preparation is now available, the domestic production of Iodine-131 radiopharmaceuticals has been made possible. Considering the production capacity of the drug within the country, it is now possible to meet orders from both local and foreign customers.
Also, it was pointed out that the production of radiopharmaceuticals and self-sufficiency in this field is one of Iran's key principles. This is seen as a way to reduce the impact of sanctions against the country.
Meanwhile, sites for the enrichment of stable isotopes of tellurium and feedstock production have been established at the Atomic Energy Organization of Iran in 2022 and 2023.
Stay up-to-date with more news on Trend News Agency's WhatsApp channel